Phase 1Recruiting
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Sponsored by ProDa BioTech, LLC
About this study
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
Enrolling at this location
Emory University Winship Cancer Institute
Atlanta, Georgia
I'm interestedThis study also enrolls at 1 other location. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.